On January 3, 2024, SomaLogic Inc announced that Jason Ryan, Chairman of the Company has issued a letter to shareholders highlighting the significant financial and strategic benefits of the transaction, and the facts behind the comprehensive strategic alternatives process that resulted in the Standard BioTools combination. Jason Ryan added that the board is confident that this transaction is the best option for stockholders to realize the substantial value of SomaLogic?s platform and together, the companies will be able to deliver on their joint mission of advancing life sciences research. Jason Ryan urged the shareholders to vote for the transaction with Standard BioTools, at the special meeting of shareholders scheduled to be held on January 4, 2024.